Opinion|Videos|October 7, 2024
Patient Selection for Chemotherapy-Based Combination Regimens in Metastatic Prostate Cancer
Author(s)Fred Saad, CQ, MD, FRCS, FCAHS
Key Takeaways
- Chemotherapy is often selected for aggressive or advanced-stage cancers requiring rapid tumor reduction.
- Patients with specific genetic mutations may benefit more from targeted therapies than chemotherapy.
The panelist discusses how patient characteristics, disease factors, and individual health status guide the decision to include or avoid chemotherapy in combination treatments for metastatic prostate cancer, weighing potential benefits against risks and quality of life considerations.
Advertisement
Video Content above is prompted by the following:
- For which patients would you choose or avoid a combination that includes chemotherapy?
Advertisement
Related to this article
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
5